Cargando…
Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer
BACKGROUND: Late gadolinium enhancement (LGE-) cardiovascular magnetic resonance (CMR) is well-validated for cardiac mass (C(MASS)) tissue characterization to differentiate neoplasm (C(NEO)) from thrombus (C(THR)): Prognostic implications of C(MASS) subtypes among systemic cancer patients are unknow...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639740/ https://www.ncbi.nlm.nih.gov/pubmed/29025425 http://dx.doi.org/10.1186/s12968-017-0390-2 |
_version_ | 1783270935482073088 |
---|---|
author | Chan, Angel T. Plodkowski, Andrew J. Pun, Shawn C. Lakhman, Yuliya Halpenny, Darragh F. Kim, Jiwon Goldburg, Samantha R. Matasar, Mathew J. Moskowitz, Chaya S. Gupta, Dipti Steingart, Richard Weinsaft, Jonathan W. |
author_facet | Chan, Angel T. Plodkowski, Andrew J. Pun, Shawn C. Lakhman, Yuliya Halpenny, Darragh F. Kim, Jiwon Goldburg, Samantha R. Matasar, Mathew J. Moskowitz, Chaya S. Gupta, Dipti Steingart, Richard Weinsaft, Jonathan W. |
author_sort | Chan, Angel T. |
collection | PubMed |
description | BACKGROUND: Late gadolinium enhancement (LGE-) cardiovascular magnetic resonance (CMR) is well-validated for cardiac mass (C(MASS)) tissue characterization to differentiate neoplasm (C(NEO)) from thrombus (C(THR)): Prognostic implications of C(MASS) subtypes among systemic cancer patients are unknown. METHODS: C(MASS) + patients and controls (C(MASS) -) matched for cancer diagnosis and stage underwent a standardized CMR protocol, including LGE-CMR (IR-GRE) for tissue characterization and balanced steady state free precession cine-CMR (SSFP) for cardiac structure/function. C(MASS) subtypes (C(NEO), C(THR)) were respectively defined by presence or absence of enhancement on LGE-CMR; lesions were quantified for tissue properties (contrast-to-noise ratio (CNR); signal-to-noise ratio (SNR) and size. Clinical follow-up was performed to evaluate prognosis in relation to C(MASS) etiology. RESULTS: The study population comprised 126 patients with systemic neoplasms referred for CMR, of whom 50% (n = 63) had C(MASS) + (C(NEO) = 32%, C(THR) = 18%). Cancer etiology differed between C(NEO) (sarcoma = 20%, lung = 18%) and C(THR) (lymphoma = 30%, GI = 26%); cardiac function (left ventricular ejection fraction: 63 ± 9 vs. 62 ± 10%; p = 0.51∣ right ventricular ejection fraction: 53 ± 9 vs. 54 ± 8%; p = 0.47) and geometric indices were similar (all p = NS). LGE-CMR tissue properties assessed by CNR (13.1 ± 13.0 vs. 1.6 ± 1.0; p < 0.001) and SNR (29.7 ± 20.4 vs. 15.0 ± 11.4, p = 0.003) were higher for C(NEO), consistent with visually-assigned diagnostic categories. C(THR) were more likely to localize to the right atrium (78% vs. 25%, p < 0.001); nearly all (17/18) were associated with central catheters. Lesion size (17.3 ± 23.8 vs. 2.0 ± 1.5 cm(2); p < 0.001) was greater with C(NEO) vs. C(THR), as was systemic disease burden (cancer-involved organs: 3.6 ± 2.0 vs. 2.3 ± 2.1; p = 0.02). Mortality during a median follow-up of 2.5 years was markedly higher among patients with C(NEO) compared to those with C(THR) (HR = 3.13 [CI 1.54–6.39], p = 0.002); prognosis was similar when patients were stratified by lesion size assessed via area (HR = 0.99 per cm(2) [CI 0.98–1.01], p = 0.40) or maximal diameter (HR = 0.98 per cm [CI 0.91–1.06], p = 0.61). C(THR) conferred similar mortality risk compared to cancer-matched controls without cardiac involvement (p = 0.64) whereas mortality associated with C(NEO) was slightly higher albeit non-significant (p = 0.12). CONCLUSIONS: Among a broad cancer cohort with cardiac masses, C(NEO) defined by LGE-CMR tissue characterization conferred markedly poorer prognosis than C(THR), whereas anatomic assessment via cine-CMR did not stratify mortality risk. Both C(NEO) and C(THR) are associated with similar prognosis compared to C(MASS) - controls matched for cancer type and disease extent. |
format | Online Article Text |
id | pubmed-5639740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56397402017-10-18 Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer Chan, Angel T. Plodkowski, Andrew J. Pun, Shawn C. Lakhman, Yuliya Halpenny, Darragh F. Kim, Jiwon Goldburg, Samantha R. Matasar, Mathew J. Moskowitz, Chaya S. Gupta, Dipti Steingart, Richard Weinsaft, Jonathan W. J Cardiovasc Magn Reson Research BACKGROUND: Late gadolinium enhancement (LGE-) cardiovascular magnetic resonance (CMR) is well-validated for cardiac mass (C(MASS)) tissue characterization to differentiate neoplasm (C(NEO)) from thrombus (C(THR)): Prognostic implications of C(MASS) subtypes among systemic cancer patients are unknown. METHODS: C(MASS) + patients and controls (C(MASS) -) matched for cancer diagnosis and stage underwent a standardized CMR protocol, including LGE-CMR (IR-GRE) for tissue characterization and balanced steady state free precession cine-CMR (SSFP) for cardiac structure/function. C(MASS) subtypes (C(NEO), C(THR)) were respectively defined by presence or absence of enhancement on LGE-CMR; lesions were quantified for tissue properties (contrast-to-noise ratio (CNR); signal-to-noise ratio (SNR) and size. Clinical follow-up was performed to evaluate prognosis in relation to C(MASS) etiology. RESULTS: The study population comprised 126 patients with systemic neoplasms referred for CMR, of whom 50% (n = 63) had C(MASS) + (C(NEO) = 32%, C(THR) = 18%). Cancer etiology differed between C(NEO) (sarcoma = 20%, lung = 18%) and C(THR) (lymphoma = 30%, GI = 26%); cardiac function (left ventricular ejection fraction: 63 ± 9 vs. 62 ± 10%; p = 0.51∣ right ventricular ejection fraction: 53 ± 9 vs. 54 ± 8%; p = 0.47) and geometric indices were similar (all p = NS). LGE-CMR tissue properties assessed by CNR (13.1 ± 13.0 vs. 1.6 ± 1.0; p < 0.001) and SNR (29.7 ± 20.4 vs. 15.0 ± 11.4, p = 0.003) were higher for C(NEO), consistent with visually-assigned diagnostic categories. C(THR) were more likely to localize to the right atrium (78% vs. 25%, p < 0.001); nearly all (17/18) were associated with central catheters. Lesion size (17.3 ± 23.8 vs. 2.0 ± 1.5 cm(2); p < 0.001) was greater with C(NEO) vs. C(THR), as was systemic disease burden (cancer-involved organs: 3.6 ± 2.0 vs. 2.3 ± 2.1; p = 0.02). Mortality during a median follow-up of 2.5 years was markedly higher among patients with C(NEO) compared to those with C(THR) (HR = 3.13 [CI 1.54–6.39], p = 0.002); prognosis was similar when patients were stratified by lesion size assessed via area (HR = 0.99 per cm(2) [CI 0.98–1.01], p = 0.40) or maximal diameter (HR = 0.98 per cm [CI 0.91–1.06], p = 0.61). C(THR) conferred similar mortality risk compared to cancer-matched controls without cardiac involvement (p = 0.64) whereas mortality associated with C(NEO) was slightly higher albeit non-significant (p = 0.12). CONCLUSIONS: Among a broad cancer cohort with cardiac masses, C(NEO) defined by LGE-CMR tissue characterization conferred markedly poorer prognosis than C(THR), whereas anatomic assessment via cine-CMR did not stratify mortality risk. Both C(NEO) and C(THR) are associated with similar prognosis compared to C(MASS) - controls matched for cancer type and disease extent. BioMed Central 2017-10-12 /pmc/articles/PMC5639740/ /pubmed/29025425 http://dx.doi.org/10.1186/s12968-017-0390-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Chan, Angel T. Plodkowski, Andrew J. Pun, Shawn C. Lakhman, Yuliya Halpenny, Darragh F. Kim, Jiwon Goldburg, Samantha R. Matasar, Mathew J. Moskowitz, Chaya S. Gupta, Dipti Steingart, Richard Weinsaft, Jonathan W. Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer |
title | Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer |
title_full | Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer |
title_fullStr | Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer |
title_full_unstemmed | Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer |
title_short | Prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer |
title_sort | prognostic utility of differential tissue characterization of cardiac neoplasm and thrombus via late gadolinium enhancement cardiovascular magnetic resonance among patients with advanced systemic cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639740/ https://www.ncbi.nlm.nih.gov/pubmed/29025425 http://dx.doi.org/10.1186/s12968-017-0390-2 |
work_keys_str_mv | AT chanangelt prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer AT plodkowskiandrewj prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer AT punshawnc prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer AT lakhmanyuliya prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer AT halpennydarraghf prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer AT kimjiwon prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer AT goldburgsamanthar prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer AT matasarmathewj prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer AT moskowitzchayas prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer AT guptadipti prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer AT steingartrichard prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer AT weinsaftjonathanw prognosticutilityofdifferentialtissuecharacterizationofcardiacneoplasmandthrombusvialategadoliniumenhancementcardiovascularmagneticresonanceamongpatientswithadvancedsystemiccancer |